An observational study in Tricuspid Regurgitation, sponsored by Abbott Medical Devices. Recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Abbott Medical Devices (part of Abbott) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational post approval study is to confirm the safety and efficacy of the TriClip System when used in routine clinical practice in the Japanese population and to fulfill post-market requirements following commercial approval in Japan.
Tricuspid Regurgitation (TR) is an abnormal condition which has both short-term and long-term consequences. TR decreases forward cardiac output and raises right-sided systemic venous pressures. This physiology will often result in hepatorenal congestion and dysfunction and, in addition, cause edema and ascites. The retrograde cardiac blood flow and volume loading also leads to further tricuspid dilatation exacerbating regurgitation over time.
The TriClip System is indicated for TR reduction in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are under the following conditions, as determined by a heart team:
The objective of the TriClip Japan post-approval study is to confirm the safety and efficacy of the TriClip System for the treatment of symptomatic severe tricuspid regurgitation in a contemporary, real-world setting in the Japanese population, using the commercially available device in accordance with its approved indications for use.
228 studies on the registry are indexed under Tricuspid Valve Insufficiency; 110 are open to participants now.
This study's planned enrollment of 250 is above the median of 200 across 95 observational studies indexed under Tricuspid Valve Insufficiency.
Browse Tricuspid Valve Insufficiency studies →Abbott Medical Devices is the lead sponsor of 540 studies on the registry; 34 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 44 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
This observational post-approval study will enroll subjects from the general Japanese population who are scheduled to undergo the TriClip procedure per the current Japan IFU.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The subjects from the general Japanese population are scheduled to undergo the TriClip procedure with commercially approved TriClip System per the current Japan Indication for Use (IFU).
Device: The TriClip System
The TriClip System procedure will be performed in accordance with the Indication for Use (IFU) in Japan. The TriClip System is a transcatheter tricuspid valve repair system used to facilitate transcatheter edge-to-edge repair of the tricuspid valve leaflets and designed to deliver and deploy the Clip
Moderate or less Tricuspid Regurgitation (TR) at 30-day visit
TR grade, defined as the proportion of subjects with TR severity classified as moderate or less, will be evaluated at the 30-day follow-up visit
Time frame: 30 days
Single Leaflet Device Attachment (SLDA) at 30-day visit
SLDA rate, defined as the proportion of subjects with SLDA, will be evaluated at 30-day follow-up visit
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 11 months after the start.
Of 47 observational studies under Tricuspid Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 106. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tricuspid Valve Insufficiency →